secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-072016
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated
--------------------------------------------------------------------------------

- Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.
- Cash, equivalents and restricted cash ~$100M; cash runway expected into H2 2026, funding PBGENE-HBV and PBGENE-DMD through Phase 1 data.
- PBGENE-HBV cleared for U.S. Phase 1 (FDA IND) and UK (MHRA); Fast Track designation granted; initial safety data presented at EASL.
- PBGENE-DMD prioritized as second wholly owned program; IND/CTA target in 2025 with clinical data expected in 2026.
- PBGENE-3243 development paused to focus resources on HBV and DMD programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025072016/0000950170-25-072016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025072016/dtil-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer